Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Delphic acquires Iqur’s diagnostics business to consolidate its position within HIV and hepatitis


20 January 2009

Delphic, a provider of specialist diagnostics for HIV and hepatitis since 2001, has acquired the diagnostics business of iQur, a biotechnology company specialising in chronic liver disease. The acquisition enables Delphic to leverage its capabilities and infrastructure to offer improved services in infectious diseases to the clinical and clinical trials markets, and to access the growing market for blood borne virus screening.

Tim Leaver, CEO of Delphic, said: “This is an important acquisition for Delphic. We have consolidated our expertise in infectious diseases and proven our ability to identify and successfully integrate complementary businesses into the group.”

iQur is a spin-out from the University of Southampton, a result of the University’s partnership with the IP2IPO Group plc (AIM: IPO), the intellectual property company specialising in commercialising university technology. It has now divested itself of its diagnostics business to concentrate on its vaccines research programme. In addition to acquiring iQur’s diagnostics business, Delphic successfully managed its own spin-out from the University of Liverpool in 2005 by acquiring its therapeutic drug monitoring service, a product used to individualise drug therapy for people with HIV and hepatitis.

Tim Leaver continued: “Personalised medicine is the future of drug therapy with technology transfer from clinical and academic settings having a pivotal role. We are already providing biomarkers and companion diagnostics for infectious diseases and we intend to apply these skills to meet patient needs in other therapy areas.”

Delphic’s investors include The Capital Fund, Ulive Enterprises (the University of Liverpool’s IP commercialisation company) and MMC Ventures Ltd.

Jonathan Coker of MMC commented: “We are delighted by this acquisition. Delphic is now well placed to exploit its leading position within the infectious diseases market. This addition to its growing portfolio of services will enhance its ability to secure both patient care and clinical trial contracts.”


Ends


Notes to Editors

About Delphic
Delphic is a specialist laboratory company with world-leading capabilities in pharmacology and pharmacogenetics. It was the first company in the world to offer an integrated diagnostics and biomarker service in HIV and is now applying that model in hepatitis. It has particular expertise in infectious diseases, including capabilities in study design and in method development and transfer, and a growing clinical trials portfolio. It is planning to apply its expertise to other therapy areas. Delphic is growing, organically and by acquisition, into a specialist biomarker and companion diagnostics company able to support the growing demand for personalised medicine in clinical therapy and in drug development. Its laboratories are certified to ISO, GCLP, CAP and CLIA. It has global reach via its own laboratories in the UK and partner laboratories in Italy, Spain, Greece and Argentina. Delphic’s headquarters are in London and its UK laboratories are in Liverpool and Kent.

Contact:
www.delphicdiagnostics.com
Tim Leaver, CEO
+44.20.7599.0777
Kathryn Winter, Communications Director
+44.20.7499.0777
kathryn.winter@delphicdiagnostics.com

About MMC Ventures
MMC Ventures Ltd (MMC) invests growth capital in UK companies. With £70m under management, MMC supports its companies through multiple funding rounds as they grow. MMC invests on behalf of private investors and smaller institutions and offers a tailored portfolio service. Since it began in 2000, MMC has established a strong track record of growing and selling businesses.

Contact:
www.mmcventures.com
Alanna Frieda
MMC Ventures
020 7361 0212
alanna.frieda@mmcventures.com

Daniela Cormano
Cardew Group – PR for MMC Ventures
020 7930 0777
daniela.cormano@cardewgroup.com


Publisher Contact Information:

Cardew Group
+44 20 7930 0777
daniela.cormano@cardewgroup.com

Company profile of Delphic Diagnostics
Past press releases of Delphic Diagnostics.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.